Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 30 to below 90 mL/min, mild or moderate impairment had no clinically meaningful effect on entrectinib disposition. Limits and monitoring This analysis does not establish use in severe impairment or dialysis. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 19, posted Oct 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding The exposure analysis found no clinically important differences with mild or moderate impairment at Cockcroft-Gault CrCl 30 to below 90 mL/min. Limits and monitoring The result does not establish dosing in severe impairment or dialysis. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 11, posted Jun 30, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding Patients with eGFR below 30 mL/min/1.73 m2 were not studied in the cited erenumab analysis. Limits and monitoring The evidence gap supplies no dose adjustment or dialysis schedule. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 25, posted Jul 17, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding At eGFR 45 or higher, renal impairment alone requires no dosage change. Use is not recommended from 30 to below 45. Below 30, in ESRD, or during dialysis the combination is contraindicated. Limits and monitoring All eGFR thresholds are in mL/min/1.73 m2. Verify both components of the prescribed tablet. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 20, posted Aug 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding At eGFR 45 or higher, renal impairment alone requires no dosage change. Use is not recommended from 30 to below 45. Below 30, in ESRD, or during dialysis the combination is contraindicated. Limits and monitoring All eGFR thresholds are in mL/min/1.73 m2. Verify both components of the prescribed tablet. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 24, posted Jun 23, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Mild or moderate impairment does not require adjustment. An adult dose has not been established for CrCl below 20 mL/min. Limits and monitoring Use caution in severe impairment. The absence of a studied regimen is not evidence for a dialysis dose. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 45, posted Jan 01, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment is expected to have little influence on systemic exposure to the active proton pump inhibitor. Limits and monitoring This pharmacokinetic prediction supplies no dialysis timing or supplemental dose. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 74, posted Apr 13, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding No renal dose change appears necessary across the renal severity groups described for eszopiclone. Limits and monitoring Choose the starting dose and ceiling for the patient's age and other risk factors. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Jan 10, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The etravirine dose does not require adjustment for renal impairment. Limits and monitoring Check the full antiretroviral regimen for interacting or renally adjusted components. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 24, posted Aug 16, 2023 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding CrCl spanning 25-178 mL/min had no meaningful influence on apparent oral clearance of everolimus in the cited analysis. Limits and monitoring Select the product, indication and monitoring plan separately. The analysis provides no dialysis dose. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 67, posted Jun 11, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild impairment has no special adjustment. In moderate or severe impairment, doses above ezetimibe 10 mg/simvastatin 20 mg require caution and close monitoring. Limits and monitoring The dose is written in ezetimibe/simvastatin order. Assess muscle symptoms and interacting drugs. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 9, posted Jan 23, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding For immunocompetent adults with herpes zoster, use 500 mg every 8 hours at CrCl at least 60, every 12 hours at 40-59, and every 24 hours at 20-39 mL/min. Below 20, give 250 mg every 24 hours. In HD give 250 mg following each dialysis session. Limits and monitoring The usual course is seven days. Genital and orolabial herpes use different regimens. The primary source is a matched generic oral tablet label. Review 1 product or source caution
The RX source names Famvir. The separately linked prescribing information is for a generic famciclovir oral tablet of matching form and strength.
DailyMed SPL version 4, posted Jan 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
